stockrowHUTCHMED (China) Limited Sponsored ADR
HCM Healthcare Drug Manufacturers Specialty & Generic
HUTCHMED (China) Limited Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $548.5 million, down 13.0% from fiscal 2024.
Follow HCM
Alert me
HUTCHMED (China) Limited Sponsored ADR (HCM) Altman Z-score
HUTCHMED (China) Limited Sponsored ADR's Altman Z-score for fiscal 2025 is 3.53, in the safe zone (above 2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | 3.53 | 0.47 |
| FY2024 | 3.06 | (0.78) |
| FY2023 | 3.84 | 1.66 |
| FY2022 | 2.18 | (7.47) |
| FY2021 | 9.65 | (2.65) |
| FY2020 | 12.30 | 0.09 |
| FY2019 | 12.21 | (3.13) |
| FY2018 | 15.34 | (11.01) |
| FY2017 | 26.36 | 19.23 |
| FY2016 | 7.13 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.71 | — | 0.86 | |
| Retained earnings / total assets | (0.22) | — | −0.30 | |
| EBIT / total assets | (0.02) | — | −0.07 | |
| Market value of equity / total liabilities | 4.56 | — | 2.74 | |
| Sales / total assets | 0.31 | — | 0.31 | |
| Altman Z-score | Safe zone | 3.53 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Safe zone | 6.45 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| HCM HUTCHMED (China) Limited Sponsored ADR | 3.5× |
| PBH Prestige Consumer Healthcare Inc. compare | 2.5× |
| ANIP ANI Pharmaceuticals, Inc. compare | 2.3× |
| BCRX BioCryst Pharmaceuticals, Inc. compare | 1.8× |
| XERS Xeris Biopharma Holdings, Inc. compare | 1.0× |
| TRLV Trulieve Cannabis Corp. compare | 1.0× |
| PRGO Perrigo Company plc compare | −0.1× |
| ALVO Alvotech compare | −1.0× |
| RGC Regencell Bioscience Holdings Limited compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets
More on HCM
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Beneish M-score
- The full statement